ZR-75-1 breast cancer xenograft model
Woodland Pharmaceuticals (Shrewsbury, MA) evaluated the antitumor activity of G1T38 in a Cell-Based Xenograft (CBX) tumor model, ZR-75-1, representing human breast cancer. Data collected from this efficacy study included animal weights, observations, and tumor dimensions. This information was used to determine agent tolerability based on weight change and gross physiologic changes, and anticancer activity based on tumor growth inhibition or regression. Study endpoint was Day 60. ZR-75-1 cells were harvested from culture and injected into immune-deficient mice and the study initiated at a mean tumor volume of approximately 150 mm 3 . Each cohort consisted of 10 tumor-bearing mice. In all studies, G1T38 and palbociclib was given as a daily oral treatment at 10, 25, 50 or 100 mg/kg. All protocols were IACUC approved and experiments were completed at Woodland Pharmaceuticals.
PK analysis in G1T38 treated wistar han rats
Wistar Han rats (16/ sex) were dosed once daily for 28 consecutive days via oral gavage. The dose levels were 2.5, 5.0 and 15 mg/kg/day and administered at a dose volume of 5 mL/kg. PK time points were collected on days 1 and 28 at alternating time points from two cohorts of three animals/ sex at approximately 0.5, 1, 2, 4, 8, 12, 18, 24 , and 36 hours (Day 28 only) postdose. All studies were conducted utilizing methods and protocols in accordance with IACUC approval at MPI Research (Mattawan, MI). KdELECT ® (DiscoveRx) was used as a follow-up to quantify binding affinity of G1T38-kinase interactions identified in the primary screen. Inhibitor binding constants (Kd values) were calculated from duplicate 11-point dose-response curves for targets that elicited >90% inhibition at 100 nM.
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